Clinical trials: Arterial Hypertension
Primary Hypertension
China Stroke Primary Prevention Trial
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT (NCT00794885)
- Testing
- Enalapril/folic acid, Enalapril maleate
- Where
- 2 sites in China
- Volunteers
- 20,702 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Glaucoma, Open-Angle
Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra
Open Angle Glaucoma Subjects with Cataract treated with Cataract Surgery plus one trabecular micro-bypass stent and one suprachoroidal stent
- Trial name
- NCT03255785
- Testing
- Cataract surgery plus one iStent and one iStent Supra implanted
- Where
- Armenia
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or…
- Trial name
- NCT01291108
- Testing
- AGN-210669, bimatoprost, bimatoprost vehicle
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Hypertension
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
This study are (1) to assess the relative bioavailability (BA) of a single oral dose of either 5 mg of Levamlodipine Maleate Tablets from CSPC or 10 mg of Amlodipine Besylate Tablet (NORVASC®) from Pfizer Inc.
- Trial name
- NCT03657550
- Testing
- Levamlodipine, Amlodipine, Amlodipine, Levamlodipine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Essential Hypertension
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32…
- Trial name
- NCT01873885
- Testing
- Experimental: Single IV Infusion Vasomera (PB1046)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Resistant Hypertension
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension
HQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3…
- Trial name
- NCT06216808
- Testing
- HyperQure Renal Denervation System
- Where
- 7 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- DeepQure Inc.
Open Angle Glaucoma, Ocular Hypertension
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT03927443
- Testing
- SDP-133, Lumigan
- Sponsor
- Sun Pharmaceutical Industries Limited
Hypertension
Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)
This was designed as a two part study comprising sequential double-dummy, placebo controlled 3-period randomized crossover studies.
- Trial name
- NCT01244035
- Testing
- Treatment A, Treatment B, Treatment C
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Portal Hypertension, TIPS
The BD Liverty™ TIPS Stent Graft Study
The objective of the study is to assess the safety and effectiveness of the BD Liverty™ TIPS Stent Graft for the treatment of the complications of portal hypertension from cirrhosis.
- Trial name
- ARCH (NCT05711316)
- Testing
- BD Liverty™ TIPS Stent Graft
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 177 people
- Sponsor
- C. R. Bard
Glaucoma, Open Angle, Ocular Hypertension
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure…
- Trial name
- NCT00140049
- Testing
- Xalacom, Cosopt
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma
InnFocus MicroShunt Versus Trabeculectomy Study
Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma…
- Trial name
- IMS (NCT01881425)
- Testing
- Glaucoma Surgery, InnFocus MicroShunt
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 732 people
- Sponsor
- InnFocus Inc.
Glaucoma
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07495852
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Glaukos Corporation
Hypertension
I PREVENT - Irbesartan In Hypertensive Diabetic Patients
To evaluate Blood Pressure (BP) reduction to the targeted values (Systolic BP ≤ 130 mmHg and Diastolic BP ≤ 80 mmHg) in hypertensive type 2 diabetic patients.
- Trial name
- NCT00362258
- Testing
- Irbesartan (Aprovel)
- Where
- Egypt
- Volunteers
- 797 people
- Sponsor
- Sanofi
Anemia, Diabetes
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
1. Aim: The aim of the clinical trial is to study the accuracy of the TensorTip device compared with registered (FDA-approved) invasive and non-invasive devices. 2.
- Conditions
- Anemia, Diabetes, Heart Disease, High Blood Pressure
- Trial name
- NCT01196533
- Testing
- Non invasive peripheral blood monitoring
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Cnoga Medical Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients.
- Trial name
- NCT00934089
- Testing
- PF-04217329, latanoprost vehicle, latanoprost
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Hypertension
The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in…
- Trial name
- NCT01130168
- Testing
- Comparator: Amlodipine, Comparator: ISMN ER
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Hypertension
Real-world Aliskiren Use in Diabetic Patients
The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.
- Trial name
- NCT01393860
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Glaucoma
EX-PRESS® P-50 and EX-PRESS® P-200
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term clinical performance and safety outcomes for EX-PRESS Glaucoma Filtration Devices Models P-50 and P-200.
- Trial name
- NCT06119178
- Testing
- EX-PRESS P-50 filtration device, EX-PRESS P-200 filtration device
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alcon Research
Hypertension
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan 40-80 mg) and COZAAR® (losartan 50-100 mg) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing…
- Trial name
- NCT02200640
- Testing
- High dose of Micardis®, once daily, Low dose of Micardis®, once daily, Low dose of COZAAR®, once daily
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.